Shandong Saito Biotechnology

Shandong Saito Biotechnology is a leading high-tech enterprise specializing in the research, development, and large-scale production of steroid drug intermediates and active pharmaceutical ingredients (APIs). The company is a pioneer in utilizing advanced biotechnology, specifically microbial transformation and biocatalysis, to convert phytosterols into key steroid precursors such as androstenedione (AD) and androstadienedione (ADD). By integrating upstream raw material production with downstream API and formulation capabilities, Saito has established a comprehensive industrial chain in the steroid hormone field. Their products serve as essential building blocks for a wide range of anti-inflammatory, hormonal, and contraceptive medications globally. The company is publicly traded on the Shenzhen Stock Exchange and continues to expand its international footprint through strategic acquisitions in Europe.